Retatrutide
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Retatrutide is an investigational peptide developed by Eli Lilly, best known as a “triple agonist” — a single molecule designed to activate three metabolic hormone receptors simultaneously: GIP, GLP-1, and glucagon. It belongs to the same broad class as semaglutide and tirzepatide but adds a third mechanism that its predecessors do not target.
It has been studied primarily in the context of weight management and obesity. In published Phase 2 research and reported Phase 3 results, retatrutide has been associated with some of the largest average weight reductions observed for an investigational drug in its class.
Retatrutide is not approved for human use. It remains in clinical development, and access outside a clinical trial is not authorized. Human data, while promising, is still emerging.
How it works
The GLP-1 and GIP components are shared with existing incretin-based therapies and are commonly associated with appetite suppression, slowed gastric emptying, and improved insulin response. The distinguishing feature of retatrutide is the glucagon receptor component, which researchers have studied for its potential role in increasing energy expenditure and promoting fat metabolism.
By engaging all three pathways together, retatrutide is designed to combine appetite reduction with increased energy use. The precise contribution of each receptor to the overall effect in humans is still being characterized.
Reported benefits
- Substantial weight reduction reported in Phase 2 and Phase 3 obesity trials
- Studied for improvements in blood-sugar-related markers
- Investigated for reduction of liver fat in metabolic dysfunction-associated steatotic liver disease (Phase 2a)
- Explored as a once-weekly injectable in trial settings
These are reported and studied findings from clinical research, not guaranteed outcomes, and the compound remains investigational.
Considerations & side effects
Because retatrutide is still in clinical development, its long-term safety profile in the general population is not fully established. In trials, the most commonly reported side effects were gastrointestinal — including nausea, diarrhea, and constipation — and appeared to be dose-related, consistent with other drugs in the incretin class.
As an unapproved compound, retatrutide is not legally available by prescription, and material sold through research-chemical channels carries no assurance of identity, purity, or sterility. It is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is retatrutide?
Retatrutide is an investigational triple hormone receptor agonist developed by Eli Lilly that activates the GIP, GLP-1, and glucagon receptors at once. It is being studied primarily for obesity and related metabolic conditions.
Is retatrutide FDA-approved?
No. As of this writing retatrutide is investigational and has not been approved by the FDA or any major regulator. It is available only through clinical trials, not by prescription.
How is retatrutide different from semaglutide or tirzepatide?
Semaglutide targets one receptor (GLP-1) and tirzepatide targets two (GIP and GLP-1). Retatrutide adds a third — the glucagon receptor — which researchers believe may contribute to its effect on energy expenditure and fat metabolism.
What has research shown so far?
In a Phase 2 trial, the highest dose was associated with substantial average weight reduction over 48 weeks, and Phase 3 data have reported some of the largest average weight-loss results seen in obesity drug trials. It has also been studied for fatty liver disease.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 2023. ↗
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 2024. ↗
- Eli Lilly. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). ↗
Related compounds
Long-acting amylin receptor agonist for weight management. Combined with semaglutide in CagriSema, showing up to 22.7% weight loss in Phase III trials.
Weight blend combining the amylin analog cagrilintide with the GIP/GLP-1 dual agonist tirzepatide, targeting satiety and glycemic pathways together. No human trial of this exact combination; research-level, sold pre-blended.
Dual-mechanism weight blend pairing the long-acting amylin analog cagrilintide with the GLP-1 agonist semaglutide (1:1). Novo Nordisk's clinical program showed greater weight loss than either component alone. Sold as a single co-lyophilized vial.